Integra LifeSciences Holdings Corporation (NASDAQ:IART) reported Q2 2017 earnings this Morning, coming in at $0.45 per share, in-line Wall Street’s estimates of $0.45 per Share. Revenue for the quarter came in at $282.16 million missing the streets estimates of $283.58 million
Analyst Coverage For Integra LifeSciences Holdings Corporation (NASDAQ:IART)
These are 2 Hold Ratings, 7 Buy Ratings .
The current consensus rating for Integra LifeSciences Holdings Corporation (NASDAQ:IART) is Buy (Score: 2.78) with a consensus target price of $52.06 , a potential (6.41% downside)Recent Insider Trading for Integra LifeSciences Holdings Corporation (NASDAQ:IART)
- On 5/25/2017 Stuart Essig, Director, sold 135,000 with an average share price of $49.90 per share and the total transaction amounting to $6,736,500.00.
- On 5/23/2017 Stuart Essig, Director, sold 140,000 with an average share price of $48.01 per share and the total transaction amounting to $6,721,400.00.
- On 5/4/2017 Glenn Coleman, VP, sold 13,865 with an average share price of $45.91 per share and the total transaction amounting to $636,542.15.
- On 5/4/2017 James M Sullivan, Director, sold 15,658 with an average share price of $45.89 per share and the total transaction amounting to $718,545.62.
- On 11/8/2016 Peter J Arduini, CEO, sold 24,009 with an average share price of $79.51 per share and the total transaction amounting to $1,908,955.59.
- On 8/23/2016 Raymond G Murphy, Director, sold 2,600 with an average share price of $86.64 per share and the total transaction amounting to $225,264.00.
Recent Trading for Integra LifeSciences Holdings Corporation (NASDAQ:IART) Shares of Integra LifeSciences Holdings Corporation closed the previous trading session at 49.56 down -6.06 -10.90% with 596,411 shares trading hands.